Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA 2016 User Fees Hold Steady For Brands, But Are Up – And Down – For Generics

Executive Summary

PDUFA, BsUFA increase moderately, while GDUFA facility fees fall for the first time.

You may also be interested in...



Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.

BsUFA III Talks Could Move Cloud-Platform Goals Forward

US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.

New Supplement Timelines, Categories Proposed For BsUFA III

The ideas could potentially address sponsor concerns about the effects of slow reviews.

Topics

UsernamePublicRestriction

Register

PS057042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel